32- and 1.78-fold higher odds for HL compared to those of the Low and Middle tertiles, respectively. There were positive associations between RDW and AHT values. CONCLUSION High RDW was associated with increased odds of hearing impairment in the Korean population with CKD.BACKGROUND/OBJECTIVES Individuals with vitiligo have an increased risk of depression, anxiety, social isolation and detrimental effects on body image/self-esteem. However, assessments of quality of life (QoL) impact have not focused on caregivers of children with vitiligo. To address this, we determined the QoL impact in parents of children with vitiligo to assess the relationship between QoL parameters and disease duration, location, and severity. METHODS We performed a cross-sectional study involving 123 parents of children diagnosed with vitiligo for at least 3 months, and who presented to the pediatric dermatology clinic of a major United States children's hospital. Parents completed a demographics survey, Quality of Life in a Child's Chronic Disease Questionnaire (QLCCDQ) and Family Dermatology Life Quality Index (FDLQI) to assess QoL measures. The lower the QLCCDQ score and higher the FLDQI score, the more quality of life is impaired. RESULTS Subject age ranged from 20 to 57, and 13.9% received mental health intervention. QLCCDQ emotional domain scores were most impaired, and severity and location of disease impacted these scores. FDLQI scores decreased as children age, indicating overall parent wellbeing increased as children age. CONCLUSIONS Childhood vitiligo has great emotional impact on the quality of life of caregivers. Recognizing this will enable dermatologist who primarily care for these patients to incorporate care giver specific interventions during clinical visits. Emotional domain scores for parents of children with vitiligo were the most impaired as much or more than of those seen in parents of children with chronic stable medical disease such as type 1 diabetes and asthma.BACKGROUND Despite improvements in the multimodality treatment for patients with locally recurrent rectal cancer (LRRC), oncological outcomes remain poor. This study evaluated the effect of induction chemotherapy and subsequent chemo(re)irradiation on the pathologic response and the rate of resections with clear margins (R0 resection) in relation to long-term oncological outcomes. METHODS All consecutive patients with LRRC treated in the Catharina Hospital Eindhoven who underwent a resection after treatment with induction chemotherapy and subsequent chemo(re)irradiation between January 2010 and December 2018 were retrospectively reviewed. Induction chemotherapy consisted of CAPOX/FOLFOX. Endpoints were pathologic response, resection margin and overall survival (OS), disease free survival (DFS), local recurrence free survival (LRFS), and metastasis free survival (MFS). https://www.selleckchem.com/products/tvb-3664.html RESULTS A pathologic complete response was observed in 22 patients (17%), a "good" response (Mandard 2-3) in 74 patients (56%), and a "poor" response (Mandard 4-5) in 36 patients (27%). An R0 resection was obtained in 83 patients (63%). The degree of pathologic response was linearly correlated with the R0 resection rate (p = 0.026). In patients without synchronous metastases, pathologic response was an independent predictor for LRFS, MFS, and DFS (p = 0.004, p = 0.003, and p = 0.024, respectively), whereas R0 resection was an independent predictor for LRFS and OS (p = 0.020 and p = 0.028, respectively). CONCLUSIONS Induction chemotherapy in addition to neoadjuvant chemo(re)irradiation is a promising treatment strategy for patients with LRRC with high pathologic response rates that translate into improved oncological outcomes, especially when an R0 resection has been achieved.The year 2020 marks the 80th anniversary of the Society of Surgical Oncology (SSO), so it is appropriate to celebrate the vision and leadership of Dr. William MacComb, who led the formation of the James Ewing Society as an alumni organization of the Memorial Hospital in New York City. The Ewing Society was later renamed and reorganized as the SSO in 1975. Dr. MacComb was elected as the first and second President of the James Ewing Society from 1940 to 1942. He was elected onto the Executive Council when it first formed in 1947 as the Secretary/Treasurer from 1947 to 1948, as Vice-President from 1948 to 1949, and then continued as a member of the Executive Council for 3 years until 1952. He was elected again as Vice President from 1958 to 1959, as President-elect from 1959 to 1960, as President for a third time from 1960 to 1961, and then as Chair of the Executive Committee from 1961 to 1962. No other person in the history of the SSO was President for multiple terms and also was one of the founding leaders. For these reasons, it would be a fitting accolade to refer to Dr. William MacComb as "the Father of the Society of Surgical Oncology" (founded as the James Ewing Society). Dr. MacComb also served as President of both the American Radium Society (1950) and the Society of Head and Neck Surgery (1969). He one of the first surgical oncologist trained in head and neck surgery, and, uniquely, one of the first physicians to be Board Certified in Radiology because of his training and publications in therapeutic radiology. Dr. MacComb made important contributions in the field of Head and Neck surgery, as a pioneer in the development of radiation therapy and radiation physics, and for advancing the use of combined surgery and radiation therapy for head and neck cancers.Although one of the most commonly performed surgical procedures in children and frequently performed as outpatient surgery, the postoperative course following tonsillectomy may include nausea, vomiting, poor oral intake, and pain. These problems may last days into the postoperative course. Although opioids may be used to treat the pain, comorbid conditions such as obstructive sleep apnea may mandate limiting the dose and the frequency of administration. Adjunctive agents may improve the overall postoperative course of patients and limit the need for opioid analgesics. Dexamethasone is a frequently administered intraoperatively as an adjunctive agent to decrease inflammation and pain, limit the potential for postoperative nausea and vomiting, and improve the overall postoperative course. The following manuscript reviews the use of dexamethasone to improve outcomes following tonsillectomy or adenotonsillectomy, discusses the controversies regarding its potential association with perioperative bleeding, and investigates options for dosing regimens which may maintain the beneficial physiologic effects while limiting the potential for bleeding.